🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Japan approves AstraZeneca's Truqap for breast cancer treatment

EditorFrank DeMatteo
Published 03/27/2024, 08:29 AM
© Reuters.
AZN
-

TOKYO - AstraZeneca (NASDAQ:AZN)'s Truqap, in combination with Faslodex, has received approval in Japan for the treatment of certain advanced breast cancers, marking a significant advancement in the therapeutic options available to patients. The Japanese Ministry of Health, Labour, and Welfare (MHLW) granted the approval for adult patients with unresectable or recurrent hormone receptor (HR)-positive, HER2-negative breast cancer that has PIK3CA, AKT1, or PTEN alterations and has progressed after endocrine therapy.

This decision comes in the wake of the CAPItello-291 Phase III trial results, which demonstrated that Truqap plus Faslodex reduced the risk of disease progression or death by 50% compared to Faslodex alone for patients with tumors demonstrating these specific biomarker alterations.

Breast cancer remains the most prevalent cancer among Japanese women, with over 90,000 new cases diagnosed in 2022. The HR-positive, HER2-negative subtype is particularly common, accounting for more than 65% of breast cancer cases. Approximately half of the advanced HR-positive breast cancer patients have tumors with PIK3CA, AKT1, or PTEN alterations, which has underscored the necessity for new treatments that can overcome resistance to current endocrine therapies.

Masakazu Toi, MD, Ph.D., from Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, emphasized the importance of this approval, noting the potential of the Truqap and Faslodex combination to extend the effectiveness of endocrine-based treatments and delay disease progression.

The approval in Japan also includes a companion diagnostic test to identify patients with the relevant biomarker alterations. AstraZeneca is anticipating a milestone payment from Astex Therapeutics upon the first commercial sale in Japan, with additional royalties to follow based on future sales.

Global regulatory applications are in process, with Truqap already approved in the US and other countries. The safety profile of the drug in combination with Faslodex aligns with previous trials, ensuring a reliable treatment option for patients.

This development represents a significant step in the ongoing battle against breast cancer, providing new hope for patients with limited treatment options after resistance to other therapies. The information for this article is based on a press release statement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.